A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) works to tackle the challenges facing TB drug development. This includes gaining support for a paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
Day One: September 24, 2014 See the Workshop Overview See the Session Recaps and Presentations from Day 2 Welcome – Objective of Meeting Speaker: Jan Gheuens, Bill & Melinda Gates Foundation Jan Gheuens summarized the progress of CPTR since its inception and stressed the importance of a coordinated approach toward regimen development. He discussed the
Day Two: September 25, 2014 See the Workshop Overview See the Session Recaps and Presentations from Day 1 EVALUATING THE IMPACT OF ENGAGEMENT ON TB DRUG DEVELOPMENT DAY TWO: SEPTEMBER 25, 2014 Objective: Discuss the level of engagement needed for the future TB drug development. Introduction Presenter: Jim Lavery, St. Michael’s Hospital Jim Lavery shared an overview
These stories link to the WHO's Working Group on New TB Drugs